Our results indicated that GA downregulated the PPARγ signaling by increasing hepatic IRF6 levels, which then weakened lipid synthesis and accumulation by downregulating lipogenesis-related factors, ultimately relieving hepatic steatosis and liver damage. The gene discussed is PPARG; the disease is fatty liver disease.